Payment overview · 2025
General Payments
$53.95
2 reported records · 2 companies
Healthcare provider profile · identity verified
Kevin Mark Taylor, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · YPSILANTI, MI · NPI 1962438788
Verified facts
What the public records show
CMS Open Payments records show Kevin Mark Taylor, M.D. received $53.95 in general payments during 2025 across 2 reported records.
Sirtex Medical Inc accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sirtex Medical Inc | Unresolved — no canonical attribution shown | $31.79 | 58.9% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $22.16 | 41.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $53.95 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIR-Spheres Microspheres Normalized: sir spheres microspheres |
Device | Sirtex Medical Inc | $31.79 | 1 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $22.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
None of this doctor’s payer companies has same-entity product evidence that passes the publication threshold. The site does not infer company ownership, affiliates, or generic manufacturers.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 824 | 228 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 92 |
| Gabapentin | Gabapentin | 268 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 244 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 43 |
| Metformin Hcl | Metformin Hcl | 219 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 214 | 60 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 204 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 204 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 201 | 59 |
| Omeprazole | Omeprazole | 200 | 65 |
| Jardiance | Empagliflozin | 185 | 41 |
| Eliquis | Apixaban | 180 | 56 |
| Lisinopril | Lisinopril | 164 | 46 |
| Allopurinol | Allopurinol | 156 | 37 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 139 | 39 |
| Furosemide | Furosemide | 131 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 129 | 34 |
| Metformin Hcl Er | Metformin Hcl | 121 | 38 |
| Trulicity | Dulaglutide | 119 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 108 | 33 |
| Indapamide | Indapamide | 106 | 30 |
| Trazodone Hcl | Trazodone Hcl | 102 | 33 |
| Carvedilol | Carvedilol | 101 | 28 |
| Tramadol Hcl | Tramadol Hcl | 101 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 94 | 30 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 26 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 88 | 25 |
| Pregabalin | Pregabalin | 87 | 11 |
| Spironolactone | Spironolactone | 85 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 29 |
| Sertraline Hcl | Sertraline Hcl | 83 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 27 |
| Glimepiride | Glimepiride | 77 | 23 |
| Ezetimibe | Ezetimibe | 75 | 20 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 73 | 32 |
| Prednisone | Prednisone | 70 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 19 |
| Januvia | Sitagliptin Phosphate | 60 | 13 |
| Losartan Potassium | Losartan Potassium | 59 | 18 |
| Potassium Chloride | Potassium Chloride | 59 | 18 |
| Warfarin Sodium | Warfarin Sodium | 54 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | suppressed |
| Clonazepam | Clonazepam | 51 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 13 |
| Atenolol | Atenolol | 48 | 14 |
| Valsartan | Valsartan | 46 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 23 |
| Montelukast Sodium | Montelukast Sodium | 43 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 12 |
| Mirtazapine | Mirtazapine | 42 | 12 |
| Alendronate Sodium | Alendronate Sodium | 41 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 37 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 18 |
| Simvastatin | Simvastatin | 36 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Ozempic | Semaglutide | 34 | suppressed |
| Famotidine | Famotidine | 32 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 19 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Valacyclovir | Valacyclovir Hcl | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | 12 |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 14 |
| Baclofen | Baclofen | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Anastrozole | Anastrozole | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ramelteon | Ramelteon | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $53.95 · 2 records | Sirtex Medical Inc | CLOTTRIEVER BOLD CATHETER, SIR-Spheres Microspheres | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error